News & Events

Learn about what's new with CMC Biologics

CMC Biologics Enters into Agreement with the PATH Malaria Vaccine Initiative for Accelerated Development and Manufacturing of Monoclonal Antibodies


Manufacture of monoclonal antibodies to the malaria parasite scheduled for CMC Biologics’ Berkeley facility

Seattle, Wash. and Berkeley, Calif. – August 12, 2015 – CMC Biologics, a global leader in clinical and commercial development and contract manufacture of therapeutic proteins, announced today it has entered into an agreement with the PATH Malaria Vaccine Initiative (MVI) for process development and manufacture of specific monoclonal antibodies to test for their capacity to protect humans from malaria infection.  

Follow Us
Join us on LinkedIn Follow us on Twitter